UCDCCC NCTN UG1 PROGRAM
UCDCCC NCTN UG1 PROGRAM
批准号:
9888340
负责人:
DAVID R GANDARA
金额:
$52.16万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
未结题
起止时间:
2019-03-06 至 2025-02-28
关键词:
AreaAwarenessBiometryCaliforniaCancer ControlClinical ResearchClinical TrialsCommunitiesComprehensive Cancer CenterEnsureFacultyGenomicsGoalsHealthHumanLaboratoriesLeadLeadershipLinkMalignant NeoplasmsMedical OncologyMolecular BiologyNCI-Designated Cancer CenterNursing ResearchPathologyPopulationRadiation OncologyRadiology SpecialtyResearch PersonnelResearch SupportResourcesRural MinoritySiteStructureSurgical SpecialtiesTranslational ResearchTranslationsbasebiomedical referral centercancer carecancer preventioncareer developmentdesignexperienceimprovedinnovationmedical specialtiesmultidisciplinarypatient populationprogramsrural underservedtumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
As the only NCI-designated cancer center for inland Northern California's approximately 6 million people, the
UC Davis Comprehensive Cancer Center (UCDCCC) provides both primary cancer care to a large and
growing population, and serves as the tertiary referral center for specialty cancer care for the region. For this
application as a NCTN Network Lead Academic Participating Site, led by Drs. David R Gandara, MD, and
Richard K Valicenti, MD, UCDCCC will leverage an already established multidisciplinary team of cancer
investigators from medical oncology, radiation oncology, surgical specialties, molecular biology/genomics,
pathology, radiology, biostatistics, nursing, and clinical research support to provide clinical trials expertise,
scientific and administrative leadership and accrual in NCTN studies across a broad range of tumor types and
throughout the NCTN group network. UCDCCC and its faculty have a long-standing and proven track record of
impactful contribution to NCI-sponsored clinical trials activities, as well as to NCI-related steering committees
and initiatives. This UG1 effort is anticipated to increase both the scope and reach of participation, including
integrating additional researchers and providing career development opportunities for new faculty and junior
investigators. With an already strong track record in translational and clinical research leadership for NCTN,
UCDCCC is poised to exploit unique institutional strengths in serving as a laboratory resource for clinical trials
and contributing to hypothesis-driven clinical research.
Based on over two decades of already serving as the clinical trials “hub” for accrual to NCI-sponsored studies
throughout North-Central California, this NCTN UG1 initiative creates a additional opportunities for UCDCCC to
both increase main site accrual and to extend access to NCTN trials into the community through the UCDCCC
Cancer Care Network and affiliate site, which includes substantial underserved, rural and minority patient
populations. In summary, UCDCCC represents an interdisciplinary organizational and leadership structure
linked to a clinical trials program that will be impactful and ensure robust accrual to NCTN trials.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
UCDCCC NCTN UG1 PROGRAM
-
批准号:10357788
-
项目类别:
-
资助金额:$55.73万
-
财政年份:2019
-
负责人:DAVID R GANDARA
-
依托单位:
UCDCCC NCTN UG1 PROGRAM
-
批准号:10584617
-
项目类别:
-
资助金额:$49.49万
-
财政年份:2019
-
负责人:DAVID R GANDARA
-
依托单位:
UCDCCC NCTN U10 Program
-
批准号:8838065
-
项目类别:
-
资助金额:$63.02万
-
财政年份:2014
-
负责人:DAVID R GANDARA
-
依托单位:
UCDCCC NCTN U10 Program
-
批准号:8605734
-
项目类别:
-
资助金额:$70.03万
-
财政年份:2014
-
负责人:DAVID R GANDARA
-
依托单位:
UCDCCC NCTN U10 Program
-
批准号:9128209
-
项目类别:
-
资助金额:$9.97万
-
财政年份:2014
-
负责人:DAVID R GANDARA
-
依托单位:
TAS::75 0849::TAS EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS
-
批准号:8352517
-
项目类别:
-
资助金额:$46.96万
-
财政年份:2011
-
负责人:DAVID R GANDARA
-
依托单位:
EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS
-
批准号:8845057
-
项目类别:
-
资助金额:$98.77万
-
财政年份:2011
-
负责人:DAVID R GANDARA
-
依托单位:
EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS
-
批准号:9038815
-
项目类别:
-
资助金额:$23.76万
-
财政年份:2011
-
负责人:DAVID R GANDARA
-
依托单位:
EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS
-
批准号:8737143
-
项目类别:
-
资助金额:$36.26万
-
财政年份:2011
-
负责人:DAVID R GANDARA
-
依托单位:--
TAS::75 0849::TAS EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS
-
批准号:8499157
-
项目类别:
-
资助金额:$109.1万
-
财政年份:2011
-
负责人:DAVID R GANDARA
-
依托单位:
Early Therapeutics Development with Phase II Emphasis
-
批准号:8014373
-
项目类别:
-
资助金额:$14.68万
-
财政年份:2006
-
负责人:DAVID R GANDARA
-
依托单位:
Early Therapeutics Development with Phase II Emphasis
-
批准号:8328531
-
项目类别:
-
资助金额:$90.79万
-
财政年份:2006
-
负责人:DAVID R GANDARA
-
依托单位:
TAS:: 75 0850 ::TAS RECOVERY ACT - ACTNOW CLINICAL TRIAL 8155
-
批准号:7933254
-
项目类别:
-
资助金额:$94.25万
-
财政年份:2006
-
负责人:DAVID R GANDARA
-
依托单位:
EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS
-
批准号:7543356
-
项目类别:
-
资助金额:$86.84万
-
财政年份:2006
-
负责人:DAVID R GANDARA
-
依托单位:--
Early Therapeutics Development with Phase II Emphasis
-
批准号:7789081
-
项目类别:
-
资助金额:$10.36万
-
财政年份:2006
-
负责人:DAVID R GANDARA
-
依托单位:
SOUTHWEST ONCOLOGY GROUP/UNIVERSITY OF CALIFORNIA, DAVIS
-
批准号:6848158
-
项目类别:
-
资助金额:$10.88万
-
财政年份:2004
-
负责人:DAVID R GANDARA
-
依托单位:
PHASE III TRIAL OF CISPLATIN & IRINOTECAN VS CISPLATIN & ETOPOSIDE IN PATIENTS W
-
批准号:6975644
-
项目类别:
-
资助金额:$0.12万
-
财政年份:2004
-
负责人:DAVID R GANDARA
-
依托单位:
PHASE I TRIAL OF E7389 (HALICHONDRIN B ANALOG)IN PATIENTS WITH ADVANCEDSOLID TUM
-
批准号:6975646
-
项目类别:
-
资助金额:$0.76万
-
财政年份:2004
-
负责人:DAVID R GANDARA
-
依托单位:
DOCETAXEL FOR METASTATIC BREAST CANCER IN PATIENTS AGED 70 YEARS & OLDER (& YOUN
-
批准号:6975645
-
项目类别:
-
资助金额:$0.08万
-
财政年份:2004
-
负责人:DAVID R GANDARA
-
依托单位:
PHASE I STUDY OF STI571 IN PATIENTS WITH MALIGNANCIES & VARYING DEGREES OF LIV
-
批准号:6975647
-
项目类别:
-
资助金额:$0.46万
-
财政年份:2004
-
负责人:DAVID R GANDARA
-
依托单位:
海外基金